Luisa Foltran

Dr. Luisa Foltran


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 August 2019 in World Journal of Gastroenterology
Verified
Journal Article
Open access
EMElena De Mattia
Elena De Mattia
Erika CecchinErika Cecchin
Erika Cecchin
Michela GuardascioneMichela Guardascione
Michela Guardascione
LFLuisa Foltran
Luisa Foltran
TRTania Di Raimo
Tania Di Raimo
GTGiuseppe Toffoli
Giuseppe Toffoli
Hepatocellular carcinoma (HCC) accounts for the majority of primary liver cancers. To date, most patients with HCC are diagnosed at an advanced tumor stage, excluding them from potentially curative therapies (i.e., resection, liver transplantation, percutaneous ablation). Treatments with palliative intent include chemoembolization and systemic therapy. Among systemic treatments, the small-molecule multikinase inhibitor sorafenib has been the only systemic treatment available for advanced HCC over 10 years. More recently, other small-molecule multikinase inhibitors (e.g., regorafenib, lenvatinib, cabozantinib) have been approved for HCC treatment. The promising immune checkpoint inhibitors (e.g., nivolumab, pembrolizumab) are still under investigation in Europe while in the US nivolumab has already been approved by FDA in sorafenib refractory or resistant patients. Other molecules, such as the selective CDK4/6inhibitors (e.g., palbociclib, ribociclib), are in earlier stages of clinical development, and the c-MET inhibitor tivantinib did not show positive results in a phase III study. However, even if the introduction of targeted agents has led to great advances in patient response and survival with an acceptable toxicity profile, a remarkable inter-individual heterogeneity in therapy outcome persists and constitutes a significant problem in disease management. Thus, the identification of biomarkers that predict which patients will benefit from a specific intervention could significantly affect decision-making and therapy planning. Germ-line variants have been suggested to play an important role in determining outcomes of HCC systemic therapy in terms of both toxicity and treatment efficacy. Particularly, a number of studies have focused on the role of genetic polymorphisms impacting the drug metabolic pathway and membrane translocation as well as the drug mechanism of action as predictive/prognostic markers of HCC treatment. The aim of this review is to summarize and critically discuss the pharmacogenetic literature evidences, with particular attention to sorafenib and regorafenib, which have been used longer than the others in HCC treatment.

24 August 2017 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
ARAnnamaria Ruzzo
Annamaria Ruzzo
FGF Graziano
F Graziano
FGFabio Galli
Fabio Galli
FGFrancesca Galli
Francesca Galli
EREliana Rulli
Eliana Rulli
Mauro MagnaniMauro Magnani
Mauro Magnani
Background: Dihydropyrimidine dehydrogenase (DPD) catabolises ∼85% of the administered dose of fluoropyrimidines. Functional DPYD gene variants cause reduced/abrogated DPD activity. DPYD variants analysis may help for defining individual patients’ risk of fluoropyrimidine-related severe toxicity. Methods: The TOSCA Italian randomised trial enrolled colon cancer patients for 3 or 6 months of either FOLFOX-4 or XELOX adjuvant chemotherapy. In an ancillary pharmacogenetic study, 10 DPYD variants (*2A rs3918290 G>A, *13 rs55886062 T>G, rs67376798 A>T, *4 rs1801158 G>A, *5 rs1801159 A>G, *6 rs1801160 G>A, *9A rs1801265 T>C, rs2297595 A>G, rs17376848 T>C, and rs75017182 C>G), were retrospectively tested for associations with ⩾grade 3 fluoropyrimidine-related adverse events (FAEs). An association analysis and a time-to-toxicity (TTT) analysis were planned. To adjust for multiple testing, the Benjamini and Hochberg’s False Discovery Rate (FDR) procedure was used. Results: FAEs occurred in 194 out of 508 assessable patients (38.2%). In the association analysis, FAEs occurred more frequently in *6 rs1801160 A allele carriers (FDR=0.0083). At multivariate TTT analysis, significant associations were found for *6 rs1801160 A allele carriers (FDR<0.0001), *2A rs3918290 A allele carriers (FDR<0.0001), and rs2297595 GG genotype carriers (FDR=0.0014). Neutropenia was the most common FAEs (28.5%). *6 rs1801160 (FDR<0.0001), and *2A rs3918290 (FDR=0.0004) variant alleles were significantly associated with time to neutropenia. Conclusions: This study adds evidence on the role of DPYD pharmacogenetics for safety of patients undergoing fluoropyrimidine-based chemotherapy.

16 February 2015 in Future Oncology
Verified
Journal Article
Closed access
LFLuisa Foltran
Luisa Foltran
GMGiovanna De Maglio
Giovanna De Maglio
NPNicoletta Pella
Nicoletta Pella
PEPaola Ermacora
Paola Ermacora
GAGiuseppe Aprile
Giuseppe Aprile
GFGianpiero Fasola
Gianpiero Fasola
To explore the prognostic value of extended mutational profiling for metastatic colorectal cancer (mCRC). We retrospectively reviewed survival results of 194 mCRC patients that were assigned to four molecular subgroups: BRAF mutated; KRAS mutated codons 12-13 only; any of KRAS codons 61-146, PIK3CA or NRAS mutations and all wild-type. Point mutations were investigated by pyrosequencing. BRAF (5.2%) and KRAS 12-13 (31.9%) mutations were associated with poorer survival (HR 2.8 and 1.76, respectively). Presenting with right-sided colon cancer, not resected primary tumor, WBC >10 × 10(9)/l, receiving less chemotherapy or no bevacizumab were all associated with inferior outcome. The all-wild-type subgroup (39.2%) reported the longest survival. Extended mutational profile combined with clinical factors may impact on survival in mCRC.

25 September 2012 in Tumor Biology
Verified
Journal Article
Closed access
PDF file
GAGiuseppe Aprile
Giuseppe Aprile
CAClaudio Avellini
Claudio Avellini
MRMichele Reni
Michele Reni
MMMicol Mazzer
Micol Mazzer
LFLuisa Foltran
Luisa Foltran
APAndrea Piga
Andrea Piga

22 June 2012 in Supportive Care in Cancer
Verified
Journal Article
Closed access
PDF file
GAGiuseppe Aprile
Giuseppe Aprile
FPFederica Edith Pisa
Federica Edith Pisa
AFA. Follador
A. Follador
LFLuisa Foltran
Luisa Foltran
FPF. De Pauli
F. De Pauli
GFG. Fasola
G. Fasola

22 November 2018 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
GTGiuseppe Toffoli
Giuseppe Toffoli
FIFederico Innocenti
Federico Innocenti
Jerry PoleselJerry Polesel
Jerry Polesel
EMElena De Mattia
Elena De Mattia
FSFranca Sartor
Franca Sartor
Erika CecchinErika Cecchin
Erika Cecchin